[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasal-disease":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,76,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100547371","collection-of-primary-human-100547371",false,"NCT06407102","Collection of Primary Human","Collection of Primary Human Nasal Epithelial Cells","BIONOSE","Inclusion Criteria:\n\n* Adult patients (age \\> 18 years) whose native language is French, or who understands French.\n* Affiliation with a French social security system (CMU accepted).\n* Informed consent, written and signed by the participant.\n* Planned rhinological surgery (meatotomy, septoplasty or turbinoplasty for example, but other surgeries as well)\n\nExclusion Criteria:\n\n* Patients under court protection, guardianship or curatorship.\n* Pregnant or breast-feeding women (positive pregnancy test for women of childbearing age).\n* Patients presenting a major alteration of the mucosa or a malignant rhinosinus pathology.",true,"ALL","18 Years","90 Years",{"count":22,"type":23},100,"ESTIMATED","INTERVENTIONAL",[26],"NA","Treatment and prevention of respiratory infections are of great interest in many medical areas. Create a physical device covered by primary human nasal cells could be very usefull in order to analyse delivery and efficiency of drugs. In this context the aim of this project is to create a collection of primary cells from the human nasal epithelium.\n\nThis collection will be realised during programmed surgery, thanks to a specific device dedicated to collect nasal cells. Then the cells will be sent to the lab in order to grow at the air-liquid interface, which is an excellent 'ex vivo' model for their study.",[29],"Nasal Disease",[31,32],"nasal cells","Respiratory epithelium","RECRUITING","2026-06-12",{"date":36,"type":37},"2026-06-16","ACTUAL",{"date":39,"type":37},"2024-12-06",{"date":41,"type":23},"2028-05-02",{"name":43,"class":44},"University Hospital, Tours","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100572331","assessing-the-efficacy-of-photodynamic-therapy-for-preventing-surgical-site-infections-100572331","NCT06731881","Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections","Leveraging Photodynamic Therapy to Inhibit Microorganisms - Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections in Nasal Surgery Patients: A Pilot Study","LIGHT","Inclusion Criteria:\n\n* Patients ≥ 16 years\n* Patients scheduled to undergo elective:\n\n  * Endoscopic Sinus Surgery (ESS) with or without adjunctive Septoplasty and\u002For Turbinoplasty\n  * Septoplasty with or without adjunctive Turbinoplasty\n  * Closed Septoplasty with or without adjunctive Turbinoplasty\n* Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history and physical examination\n* Willing and able to provide written informed consent prior to participation in the clinical investigation\n* Willing and able to comply with all study related procedures\n\nExclusion Criteria:\n\n-• Patients undergoing open septorhinoplasty, anterior or septal biopsies, or post cautery\n\n* Congenital or acquired immunodeficiency, bone marrow disease, diabetes, autoimmune conditions requiring immunosuppressive treatment, any immunosuppressive medication at the time of consent or within the last 4 weeks before randomisation\n* Primary or secondary ciliary dyskinesia, cystic fibrosis\n* Patients who have received antibiotics within a week before randomisation\n* Patients who receive prophylactic antibiotics or antibiotics prior to discharge\n* Systemic steroid treatment less than 4 weeks before randomisation\n* History of frequent nose bleeds, or a condition that increases the risk of excessive bleeding\n* Undergoing active cancer treatment at time of consent\u002F or planning to start cancer treatment within trial period or completed cancer treatment within the last 4 weeks\n* Any disease, condition (medical or surgical), or drug or alcohol abuse, which, in the opinion of the investigator, might compromise the study results, or would place the patient at increased risk of infection\n* Previously treated with radiation on the face, head, or neck regions\n* Female patients who are pregnant or breastfeeding at the time of consent\n* Received a study drug in a clinical trial for an investigational drug within the previous 30 days from consent, or 5 half-lives, whichever is longer\n* Used antimicrobial wash or wipes within 7 days of randomisation or during the study period\n* Patients with allergies \u002F hypersensitivity to methylene blue, polymethyl methacrylate (PMMA), or to chlorhexidine gluconate (CHG)","16 Years",{"count":56,"type":23},80,[26],"This is a randomised, unblinded interventional device proof of concept pilot trial in which patients undergoing nasal surgery will be selected for either photodisinfection therapy (PDT) with the Steriwave™ ND System, or control with nares swabbed with 'photosensitizer formulation' preoperatively.\n\nThis trial will primarily assess the safety and efficacy of nasal photodisinfection treatment in decreasing post-operative events in patients undergoing nasal surgery. After signing informed consent, and before surgery, participants will receive a baseline culture of the anterior nares to determine nasal bacterial colonization and will have a flexible nasendoscopy to determine their Lund-Kennedy (LK) endoscopic score. Subjects will then be randomised to nasal PDT (which includes two applications of 'photosensitizer formulation' \\[0.01% methylene blue with 0.25% chlorhexidine solution\\], two minutes apart), along with light therapy, or control with nares swabbed twice with 'photosensitizer formulation' with two minutes in between (no light therapy). Following treatment, participants will be re-cultured (2 weeks after the surgery ± 7 days) and reviewed for antibiotic use and surgical site infection (SSI) using LK endoscopic scoring. At 30 days, all participants will be followed up by telephone to review if they received antibiotics for presumed postoperative infection. Standard post-operative care will be provided according to the type of surgery performed. Any required interventions post-operatively will be documented.",[60,29,61],"Surgery","Light; Therapy, Complications",[63,64,65,66],"nasal surgery","nasal photodisinfection","decolonisation","surgical site infection","2026-06-10",{"date":69,"type":37},"2026-06-11",{"date":71,"type":37},"2025-06-04",{"date":73,"type":23},"2026-06-30",{"name":75,"class":44},"Guy's and St Thomas' NHS Foundation Trust",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100582745","dexmedetomidine-and-agitation-after-nasal-surgery-100582745","NCT06867302","Dexmedetomidine and Agitation After Nasal Surgery","Effectiveness of Single Bolus Versus Continuous Infusion of Dexmedetomidine in Mitigating Agitation in Adults Undergoing Nasal Surgery: a Prospective Randomized Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologist (ASA) Ⅰ or II\n* Adults with body mass index (BMI) \\\u003C 30 Kg\u002Fm\n* Underwent elective nasal surgery.\n\nExclusion Criteria:\n\n* Significant comorbidity like hepatic, renal, or cardiac disease\n* Auditory impairment\n* Cognitive dysfunction\n* Substance abuse\n* Allergy to the studied medicines\n* Planned intensive care admission after the surgery.","50 Years",{"count":85,"type":23},50,[26],"The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.",[29,89],"Agitation, Emergence",[91,92,93],"Dexmedetomidine","Emergence agitation","Nasal surgery","2025-03-05",{"date":96,"type":37},"2025-03-10",{"date":98,"type":37},"2025-03-01",{"date":100,"type":23},"2025-10-01",{"name":102,"class":44},"Fayoum University Hospital",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":18,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":113,"briefSummary":115,"conditions":116,"keywords":120,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":45},"100555062","phase-4-comparison-of-remimazolam-and-propofol-for-recovery-of-ambulatory-upper-airway-surgery-100555062","NCT06507202","Comparison of Remimazolam and Propofol for Recovery of Ambulatory Upper Airway Surgery","Comparison of Remimazolam Versus Propofol-based General Anesthesia on Postoperative Quality of Recovery in Patients Undergoing Ambulatory Upper Airway Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adult patients (age 19 or older) undergoing ambulatory upper respiratory tract (nasal cavity, oral cavity, pharynx, larynx) surgery under general anesthesia\n* American Society of Anesthesiologists physical class classification I, II, and III\n\nExclusion Criteria:\n\n* Patients who refused to participate in the study\n* Pregnant patients\n* Patients with a history of hypersensitivity to drugs or additives used during surgery\n* Patients with acute narrow-angle glaucoma\n* Alcohol or drug dependent patients\n* Patients with Child-Pugh class C liver dysfunction","19 Years",{"count":112,"type":23},116,[114],"PHASE4","The purpose of this study is to compare the effects of remimazolam and propofol on postoperative recovery time, complications, and safety in patients undergoing ambulatory upper airway surgery under general anesthesia.",[117,118,119,29],"Laryngeal Disease","Pharyngeal Diseases","Oral Cavity Disease",[121,122,123],"remimazolam","upper airway surgery","ambulatory surgery","2024-07-11",{"date":126,"type":37},"2024-07-18",{"date":128,"type":37},"2024-01-22",{"date":130,"type":23},"2025-03-22",{"name":132,"class":44},"Chung-Ang University Gwangmyeong Hospital",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":18,"minAge":140,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":24,"phases":144,"briefSummary":145,"conditions":146,"keywords":150,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100552849","study-on-the-efficacy-and-safety-of-a-device-for-post-op-recovery-in-pediatric-adenectomyadenotonsillectomy-100552849","NCT06478433","Study on the Efficacy and Safety of a Device for Post-op Recovery in Pediatric Adenectomy\u002FAdenotonsillectomy.","\"Efficacy and Safety Study of the Medical Device Munatoril® Aerosol Combo in the Recovery of Nasal Homeostasis in Pediatric Patients Undergoing Adenoidectomy or Adenotonsillectomy.\"","Inclusion Criteria:\n\n* Patients of either sex aged 2 to 17 years who are candidates for adenoidectomy or adenotonsillectomy surgery.\n* Acquisition and signing of informed consent by the legal guardian.\n\nExclusion Criteria:\n\n* Syndromic patients.\n* Patients allergic to any substance in the study formulations.\n* Patients who have used intranasal corticosteroids, topical or systemic corticosteroids, or any intranasal medication in the week prior to study entry.\n* Active respiratory infection in the 2 weeks prior to study entry.\n* Patients with a history of chronic epistaxis or immunodeficiency.","2 Years","17 Years",{"count":143,"type":23},90,[26],"The objective of this prospective pre-market interventional clinical study is to evaluate the efficacy and safety of the medical device Munatoril® Aerosol Combo in its different modalities of use, through the analysis of clinical and subjective outcomes in children operated on adenoidectomy or adenotonsillectomy, compared with a hypertonic solution and an over-the-counter isotonic solution (control group).\n\nThe primary question it aims to answer is whether the components prensent in Munatoril provide a benefit and whether they play a role in the recovery of nasal homeostasis following adeinodectomy and adenotonsillectomy compared with an over-the-counter hypertonic saline solution.\n\nEndpoints Evaluation of subjective longitudinal differences (intragroup over-time change) and differences between study group and control group (intergroup difference) regarding the use of the medical device, obtained following the protocol, with assessment at 8, 15 and 30 days after surgery by Likert Scale Score for tolerability, and at 0, 15 and 30 days by SNOT22 Score and Lund-Kennedy Endoscopic Score for efficacy.\n\nIn addition, there is a recording of any adverse events in both groups at 8, 15 and 30 days post-surgery, and an inter-group comparative evaluation.\n\nParticipants: Pediatric patients who are candidates for adenoidectomy or adenotonsillectomy surgery at the study site facility will be systematically evaluated preoperatively for inclusion in the clinical trial and possibly recruited. Follow-up will last 30 days.",[147,148,149,29],"Adenoidal Disorder","Tonsillitis","Otorhinolaryngologic Diseases",[151],"nasal irrigation","NOT_YET_RECRUITING","2024-07-02",{"date":155,"type":37},"2024-07-03",{"date":157,"type":23},"2024-12-01",{"date":159,"type":23},"2026-06-01",{"name":161,"class":162},"Pharmaluce srl","INDUSTRY"]